Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands as an investigational adjunct for rheumatoid arthritis: what the published clinical evidence actually shows, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México — always in coordination with the patient's treating rheumatologist. No prices are published online; every case is reviewed in a free medical evaluation, then quoted in writing.
TL;DR
Mesenchymal stem cell (MSC) therapy is an investigational, physician-supervised option being studied as an adjunct for rheumatoid arthritis — most often for patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Published phase I/II trials (including a 172-patient Wang 2013 cohort of umbilical-cord MSCs and the Cx611 multicentre phase Ib/IIa with allogeneic adipose-derived MSCs) report favorable short-term safety and an early efficacy signal, and a 2023 systematic review and meta-analysis confirmed the safety pattern. None of this replaces guideline-based rheumatology care. At Regeneris Therapy in Cancún, México, every case starts with a free medical evaluation, coordinated with your treating rheumatologist where applicable, and a personalized written quote is delivered only after.
The condition
Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease in which the body's immune system attacks the synovial lining of the joints, driving pain, swelling, morning stiffness, and — over time — joint damage. Unlike osteoarthritis, which is primarily mechanical wear, RA is fundamentally an immune-mediated process: it can affect multiple joints symmetrically, often the small joints of the hands, wrists, and feet, and can also affect extra-articular systems including the eyes, lungs, skin, and cardiovascular system. Standard rheumatology care has transformed prognosis over the last two decades, but a meaningful fraction of patients still respond inadequately to currently available drugs.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in rheumatoid arthritis is encouraging but still preliminary. The published human studies are mostly phase I/II trials and small cohorts focused on safety, with a 2023 systematic review and meta-analysis confirming the favorable short-term safety pattern. Reviewers — including the field's own systematic reviewers — are explicit that larger, longer randomized controlled trials are still needed before MSCs can be considered an established treatment for RA. The notes below summarize the strongest sources we cite and what each does and does not show. None of it guarantees an individual outcome.
An ongoing prospective study from a Chinese multicentre group enrolled 172 patients with active rheumatoid arthritis who had inadequate response to traditional medication. Patients were assigned to disease-modifying anti-rheumatic drugs (DMARDs) plus medium without UC-MSCs, or DMARDs plus a single intravenous infusion of allogeneic umbilical-cord MSCs (4×10⁷ cells). No serious adverse effects were observed during or after infusion, serum levels of TNF-α and IL-6 decreased after the first treatment, and clinical improvement in disease-activity measures was reported over the follow-up window. The authors framed the results as supportive of safety and a possible immunomodulatory signal — not as definitive efficacy.
A multicentre, dose-escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial evaluated Cx611 — expanded allogeneic adipose-derived MSCs — in 53 adults with active refractory rheumatoid arthritis who had failed at least two biologic agents. Three intravenous infusions (1, 2, or 4 million cells/kg, or placebo) on days 1, 8, and 15 were generally well tolerated, without evidence of dose-related toxicity at the doses and time period studied, and a trend toward clinical efficacy was observed. This is one of the cleanest dose-finding safety datasets to date for allogeneic MSC infusion in RA.
A single-arm, open-label, non-randomized phase I/IIa pilot trial enrolled 15 adults with active rheumatoid arthritis to receive a single intravenous infusion of autologous adipose-derived MSCs (2×10⁸ cells), with follow-up at weeks 4, 12, 26, and 52. The authors reported no acute or long-term serious adverse events, with improvement in joint-function endpoints over the year. Sample size is modest and the design is uncontrolled, so the data should be read as safety- and feasibility-oriented rather than as efficacy proof.
A systematic review and meta-analysis of clinical trials of MSC therapy in rheumatoid arthritis pooled data across multiple studies and reported a favorable short-term safety profile, without life-threatening events in subjects with RA, and a trend toward clinical efficacy. The authors specifically note that clinical efficacy improvements were not sustained at 12 months without continuous treatment — a finding clinicians should communicate honestly with patients before any MSC course is considered. This is the most rigorous synthesis available at the time of writing and anchors a responsible patient conversation.
Mechanistic context that frames the entire MSC-in-autoimmunity literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing their therapeutic benefit comes chiefly from secreted, paracrine factors — exosomes, growth factors, cytokines — rather than from engraftment and tissue replacement. In RA, this mechanism is invoked to explain how a single intravenous MSC infusion may modulate T-cell balance, lower TNF-α and IL-6, and dampen synovial inflammation — without literally rebuilding cartilage from scratch.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational and immunologically interesting for RA, and shows an early safety and efficacy signal in phase I/II studies and one well-powered meta-analysis — but it remains investigational, must not replace guideline-based rheumatology care, and benefits may not persist long-term without continuous treatment. Whether it is reasonable for your specific case is a medical question — answered only in evaluation, coordinated with your rheumatologist, never assumed from a search query.
Candidacy
MSC therapy for rheumatoid arthritis is not a first-line treatment, and it is not a fit for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one. We do not initiate an MSC course in RA without coordination with your treating rheumatologist.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish. For an autoimmune disease like RA, the regulatory and coordination layer matters even more than usual.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México.
Cells used in our protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic, and especially important when systemic infusion is being considered in an immunologically active disease.
Every protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México. For RA we explicitly coordinate with your treating rheumatologist before, during, and after any MSC course; decisions are documented in your written plan and shared with your home specialist.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and rest on a single short itinerary; our team helps coordinate the medical side — including communication with your home rheumatologist — from your first message.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package. Every RA case starts with a structured physician evaluation, includes coordination with your treating rheumatologist, and ends with a written plan and a personalized quote — so you can make an informed decision before committing.
Share your rheumatology diagnosis, recent disease-activity scores (DAS28 if available), labs (RF, anti-CCP, ESR, CRP), imaging, current medications (DMARDs, biologics, JAKi, steroids), and any comorbidities. A Regeneris physician reviews your case — by message or video first if you are traveling from outside Cancún — and answers honestly whether MSC therapy is reasonable to consider for you.
We request authorization to communicate with your treating rheumatologist about timing, expected effect on disease activity, and how MSC therapy fits the broader treat-to-target plan. We do not proceed if your specialist does not consider it appropriate at this point in your treatment.
If MSC therapy is appropriate, you receive a written plan describing cell source, route of administration, number of sessions, follow-up cadence with both Regeneris and your rheumatologist, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up shared with your rheumatologist. We reassess outcomes honestly using objective disease-activity measures — including the explicit possibility that the response does not justify a repeat course.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in: free evaluation first, rheumatology coordination second, written quote only after we understand your case.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence; we are deliberately conservative because honesty is the only defensible position in a YMYL medical field, and especially in an autoimmune disease with established standard-of-care therapy.
FAQ
The questions patients ask us most when considering MSC therapy for rheumatoid arthritis at our clinic in Cancún, México.
No — and any clinic that says otherwise is overstating the evidence. Rheumatoid arthritis is a chronic autoimmune disease; current therapies (standard or investigational) manage it, they do not eliminate it. Published clinical evidence — including the Wang 2013 UC-MSC cohort of 172 patients, the Cx611 phase Ib/IIa trial in refractory RA (Álvaro-Gracia 2017), and the 2023 Mesa systematic review and meta-analysis — supports a favorable short-term safety signal and a trend toward clinical efficacy, but the meta-analysis explicitly noted that gains were not sustained at 12 months without continuous treatment. A Regeneris physician will tell you honestly, after evaluation and in coordination with your rheumatologist, whether MSC therapy is reasonable to consider as an adjunct to your current care.
No, and you should not stop them on your own. MSC therapy is studied and offered as an adjunct, not a replacement, for your guideline-based rheumatology regimen. Any change to your methotrexate, biologic, or JAK inhibitor is a decision for your treating rheumatologist, not for us. If your specialist has not agreed that MSC therapy is appropriate at this point in your treatment, we will not proceed.
For RA, the most studied route in the published literature is intravenous infusion of allogeneic MSCs — placing the cell preparation into the bloodstream so they can act systemically through paracrine signaling (release of exosomes and cytokines that modulate T-cell balance and lower TNF-α and IL-6). The Wang 2013 study used a single IV infusion of umbilical-cord MSCs (4×10⁷ cells); the Cx611 phase Ib/IIa trial used three IV infusions (1-4 million cells/kg) on days 1, 8, and 15. Your written plan describes exactly which route and dosing schedule apply to you, and why.
In published phase I/II studies, including the Cx611 multicentre trial and the Vij 2022 autologous pilot, the early safety profile of IV MSC infusion in RA has been acceptable, without dose-related toxicity at the doses and timepoints studied. The 2023 Mesa systematic review and meta-analysis confirmed a favorable short-term safety pattern without life-threatening events. Common risks of any IV infusion — temporary fatigue, mild infusion reactions, low risk of infection — are reviewed with you in your evaluation. Patients with active malignancy, active infection, pregnancy, or uncontrolled immunosuppression are generally deferred without coordinated specialist review. Long-term comparative safety in RA still requires larger, longer trials.
Onset is gradual, not immediate. Anti-inflammatory and immunomodulatory effects can build over several weeks; broader improvement in disease-activity measures, when it occurs, is typically observed over one to several months. We schedule structured follow-up to assess symptoms, objective disease-activity scores, and inflammatory markers honestly over that window — and we share that follow-up with your rheumatologist. The 2023 Mesa meta-analysis noted that improvements were not always sustained at 12 months without continued treatment, which we discuss openly before any decision.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, coordination with your treating rheumatologist second, then a written plan and a personalized quote that reflect your specific case, comorbidities, and goals. We chose this approach because medicine — especially in an autoimmune disease that depends on ongoing specialist care — is not a catalog purchase. Your full quote is delivered in writing after evaluation, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.
ContinueTravel, evaluation, and follow-up logistics for cross-border patients coming to our clinic in Cancún, México.
ContinueA 2026 comparison of cost, regulation, available cell types, and travel logistics for cross-border regenerative care.
ContinueSend your rheumatology records — we'll route your message to a physician for a free medical evaluation.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for rheumatoid arthritis is investigational; outcomes vary by patient, disease activity, and protocol, and no individual response is guaranteed. MSC therapy is offered exclusively as an adjunct to guideline-based rheumatology care — never a substitute — and only after coordination with your treating rheumatologist. The decision to pursue MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your rheumatology diagnosis, recent labs (RF, anti-CCP, ESR, CRP), current medications, and disease-activity scores. A Regeneris physician will review your case from Cancún, México, coordinate with your rheumatologist where appropriate, and tell you — honestly — whether MSC therapy is worth considering, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.